Andrew Wagner

Andrew Wagner is a sarcoma medical oncologist focused on undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, two of the most common adult soft tissue sarcomas with poor outcomes. His research has investigated checkpoint immunotherapy in these histotypes and evaluated novel combinations of CDK4 inhibitors and MDM2 antagonists in CDK4/MDM2 co-amplified liposarcomas. He is a key investigator in multi-institutional sarcoma clinical trial networks and contributes to the molecular characterization and drug target identification in rare STS subtypes.